Mitogen-Activated Protein Kinase Kinase 2 Inhibitors
- Name
- Mitogen-Activated Protein Kinase Kinase 2 Inhibitors
- Accession Number
- DBCAT005517
- Description
Not Available
- Drugs
Drug Drug Description Selumetinib A MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). - Drugs & Drug Targets